

Alaska Medicaid Pharmacy and Therapeutics Committee Meeting

April 17, 2020

Committee Members only, Frontier Building,

3601 C Street; Room **890/896**

Agenda (revised)

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Public Call in: 1.800.315.6338. Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**, including health care professionals

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red*** and **Blue**** are classes where new information exists and industry testimony will be taken. Classes shown in **Green** are classes where no significant changes have been noted and no industry testimony will be taken.

*New information includes: *new drugs or **new indications, new warnings, new head to head clinical evidence.*

4. Class review, discussion & vote.

AK Treatment Class	Drug Class	Status
Single Class Review	Hereditary Angioedema	BLUE
	Hemophilia	BLUE
Cardiovascular	ACE Inhibitor & Renin Inhibitors	GREEN
	Angiotensin Receptor Blockers (ARB)	BLUE
	Angiotensin Modulator/CCB Combinations	GREEN
	Antianginal and Anti-ischemic agents	GREEN
	Anticoagulants	BLUE
	Beta-Blockers	GREEN
	Calcium Channel Blockers	RED
	Erythropoiesis Stimulating agents	BLUE
	Lipotropics, other	BLUE
	PCSK-9 Inhibitors	BLUE
	Platelet Aggregation Inhibitors	RED
	Pulmonary Arterial Hypertension	BLUE
Anti-Infective	Antifungals, oral	BLUE
	Antifungals, topical	GREEN
	Antivirals, influenza	BLUE
	Fluoroquinolones, oral	BLUE
	Hepatitis B agents	GREEN
	Hepatitis C agents	BLUE
	Otic Antibiotics	GREEN
	Bladder Relaxant Preparations	BLUE
	Vaginal Antibiotics	GREEN

7. **Break as needed** – 15 minutes
8. **Review minutes** from January 2020 meeting
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until April 2, 2020 at 4:00pm AK local time. Forms may be found at: http://dhss.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx.

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to erin.narus@alaska.gov or via mail to 4501 Business Park Blvd, Bldg L, Anchorage, AK 99503. Submissions should be received no later than April 14, 2020 to allow inclusion in the meeting.

Next Meeting Date: September 18, 2020